Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Correction to: Benefit:Risk Profile of Budesonide in Obstructive Airways Disease.

Tashkin DP, Lipworth B, Brattsand R.

Drugs. 2019 Nov;79(17):1911. doi: 10.1007/s40265-019-01220-y.

PMID:
31691125
2.

Benefit:Risk Profile of Budesonide in Obstructive Airways Disease.

Tashkin DP, Lipworth B, Brattsand R.

Drugs. 2019 Nov;79(16):1757-1775. doi: 10.1007/s40265-019-01198-7. Review. Erratum in: Drugs. 2019 Nov;79(17):1911.

3.

20α- and 20β-dihydrocortisone may interfere in LC-MS/MS determination of cortisol in saliva and urine.

Israelsson M, Brattsand R, Brattsand G.

Ann Clin Biochem. 2018 May;55(3):341-347. doi: 10.1177/0004563217724178. Epub 2017 Sep 20.

PMID:
28726485
4.

The role of intracellular esterification in budesonide once-daily dosing and airway selectivity.

Brattsand R, Miller-Larsson A.

Clin Ther. 2003;25 Suppl C:C28-41. Review.

PMID:
14642802
5.

Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model.

Graffner-Nordberg M, Fyfe M, Brattsand R, Mellgård B, Hallberg A.

J Med Chem. 2003 Jul 31;46(16):3455-62.

PMID:
12877583
6.

Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data.

Edsbäcker S, Brattsand R.

Ann Allergy Asthma Immunol. 2002 Jun;88(6):609-16. Review.

PMID:
12086369
7.

Molecular mechanisms of decreased steroid responsiveness induced by latent adenoviral infection in allergic lung inflammation.

Yamada K, Elliott WM, Brattsand R, Valeur A, Hogg JC, Hayashi S.

J Allergy Clin Immunol. 2002 Jan;109(1):35-42.

PMID:
11799363
8.

Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat.

Miller-Larsson A, Gustafsson B, Persson CG, Brattsand R.

Aliment Pharmacol Ther. 2001 Dec;15(12):2019-25.

9.
10.

Latent adenoviral infection modifies the steroid response in allergic lung inflammation.

Yamada K, Elliott WM, Hayashi S, Brattsand R, Roberts C, Vitalis TZ, Hogg JC.

J Allergy Clin Immunol. 2000 Nov;106(5):844-51.

PMID:
11080705
11.

Prolonged airway activity and improved selectivity of budesonide possibly due to esterification.

Miller-Larsson A, Jansson P, Runström A, Brattsand R.

Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1455-61.

PMID:
11029361
12.

Adrenalectomy permits a late, local TNF-alpha release in LPS-challenged rat airways.

Miller-Larsson A, Runström A, Brattsand R.

Eur Respir J. 1999 Jun;13(6):1310-7.

13.

The ideal steroid.

Brattsand R.

Pulm Pharmacol Ther. 1999;12(2):119-22. Review. No abstract available.

PMID:
10373394
14.

Glucocorticoids augment fibroblast-mediated contraction of collagen gels by inhibition of endogenous PGE production.

Sköld CM, Liu XD, Zhu YK, Umino T, Takigawa K, Ohkuni Y, Ertl RF, Spurzem JR, Romberger DJ, Brattsand R, Rennard SI.

Proc Assoc Am Physicians. 1999 May-Jun;111(3):249-58.

PMID:
10354365
15.

Improved effects of novel glucocorticosteroids on immune-induced epithelial pathophysiology.

Zareie M, Brattsand R, Sherman PM, McKay DM, Perdue MH.

J Pharmacol Exp Ther. 1999 Jun;289(3):1245-9.

PMID:
10336512
16.

Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line In vitro.

Wieslander E, Delander EL, Järkelid L, Hjertberg E, Tunek A, Brattsand R.

Am J Respir Cell Mol Biol. 1998 Sep;19(3):477-84.

PMID:
9730876
17.

Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue.

Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R.

Drug Metab Dispos. 1998 Jul;26(7):623-30.

PMID:
9660844
18.

Effects of orally inhaled budesonide in seasonal allergic rhinitis.

Greiff L, Andersson M, Svensson C, Linden M, Wollmer P, Brattsand R, Persson CG.

Eur Respir J. 1998 Jun;11(6):1268-73.

19.

Antioxidative properties of organotellurium compounds in cell systems.

Wieslander E, Engman L, Svensjö E, Erlansson M, Johansson U, Linden M, Andersson CM, Brattsand R.

Biochem Pharmacol. 1998 Mar 1;55(5):573-84.

PMID:
9515568
20.
21.

Interleukin-2 and -4 induce resistance of granulocyte-macrophage colony-stimulating factor to corticosteroids.

Larsson S, Brattsand R, Linden M.

Eur J Pharmacol. 1997 Sep 10;334(2-3):265-71.

PMID:
9369357
22.

Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation.

McKay DM, Brattsand R, Wieslander E, Fung M, Croitoru K, Perdue MH.

J Pharmacol Exp Ther. 1996 Apr;277(1):403-10.

PMID:
8613948
23.

Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies.

Brattsand R, Linden M.

Aliment Pharmacol Ther. 1996;10 Suppl 2:81-90; discussion 91-2. Review.

PMID:
8899106
24.

Topical anticolitic efficacy and selectivity of the glucocorticoid budesonide in a new model of acetic acid-induced acute colitis in the rat.

Fabia R, Ar'Rajab A, Willén R, Brattsand R, Erlansson M, Svensjö E.

Aliment Pharmacol Ther. 1994 Aug;8(4):433-41.

PMID:
7986968
25.

Seasonal variation in the function of blood monocytes obtained from healthy nonsmokers, asymptomatic smokers, and smokers with chronic bronchitis.

Linden M, Larson M, Prellner T, Brattsand R, Laitinen LA.

Chronobiol Int. 1994 Aug;11(4):266-72.

PMID:
7954908
26.

Diaryl tellurides as inhibitors of lipid peroxidation in biological and chemical systems.

Andersson CM, Brattsand R, Hallberg A, Engman L, Persson J, Moldéus P, Cotgreave I.

Free Radic Res. 1994 Jun;20(6):401-10.

PMID:
8081455
27.

Experimental granulomatous alveolitis in rat. Effect of antigen manipulation, smoke exposure and route of administration.

Bjermer L, Cai YG, Särnstrand B, Brattsand R.

Sarcoidosis. 1994 Mar;11(1):52-7.

PMID:
7518608
29.

Antioxidant activity of some diarylselenides in biological systems.

Andersson CM, Hallberg A, Linden M, Brattsand R, Moldéus P, Cotgreave I.

Free Radic Biol Med. 1994 Jan;16(1):17-28.

PMID:
8299991
30.

Sephadex-induced granulomatous alveolitis in rat: effects of antigen manipulation.

Bjermer L, Sandström T, Särnstrand B, Brattsand R.

Am J Ind Med. 1994 Jan;25(1):73-8.

PMID:
7509565
31.

Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis.

Linden M, Rasmussen JB, Piitulainen E, Tunek A, Larson M, Tegner H, Venge P, Laitinen LA, Brattsand R.

Am Rev Respir Dis. 1993 Nov;148(5):1226-32.

PMID:
8239158
32.

Oral availability of fluticasone propionate.

Andersson P, Brattsand R, Dahlström K, Edsbäcker S.

Br J Clin Pharmacol. 1993 Aug;36(2):135-6. No abstract available.

33.

Alpha-(phenylselenenyl)acetophenone derivatives with glutathione peroxidase-like activity. A comparison with ebselen.

Cotgreave IA, Moldéus P, Brattsand R, Hallberg A, Andersson CM, Engman L.

Biochem Pharmacol. 1992 Feb 18;43(4):793-802.

PMID:
1540234
34.

Cytotoxicity of human phagocytes studied in vitro in a novel model based on neutral red absorbtion.

Brattsand R, Delander EL, Peterson C, Wieslander E.

Agents Actions. 1991 Sep;34(1-2):35-7.

PMID:
1793048
35.

Attenuation of bradykinin-induced mucosal inflammation by topical budesonide in rat trachea.

Brattsand R, O'Donnell SR, Miller-Larsson A, Rauchle KL.

Agents Actions. 1991 Sep;34(1-2):200-2.

PMID:
1793030
36.

Native fluorescence of extravasated proteins. A new method for quantitation of macromolecular vascular leakage.

Miller-Larsson A, Brattsand R.

J Pharmacol Methods. 1991 May;25(3):251-62.

PMID:
2056754
37.

An in situ preparation of rat trachea for studying the effects of mucosally applied anti-asthma drugs on mediator-induced plasma exudation.

O'Donnell SR, Miller-Larsson A, Brattsand R, Rauchle KL.

Agents Actions Suppl. 1991;34:491-5.

PMID:
1793080
38.

Effects of an inhaled corticosteroid, budesonide, on alveolar macrophage function in smokers.

Bergstrand H, Björnson A, Blaschke E, Brattsand R, Eklund A, Larsson K, Linden M.

Thorax. 1990 May;45(5):362-8.

40.

Topical anti-inflammatory activity of the glucocorticoid budesonide on airway mucosa. Evidence for a "hit and run" type of activity.

Miller-Larsson A, Brattsand R.

Agents Actions. 1990 Jan;29(1-2):127-9. No abstract available.

PMID:
2327315
41.

Which markers of inflammation should be used in therapeutic intervention studies of CB/COAD?

Venge P, Brattsand R, Laitinen LA, Persson CG.

Agents Actions Suppl. 1990;30:289-94. Review. No abstract available.

PMID:
2239539
42.

Inflammatory indices for chronic bronchitis and chronic obstructive airway disease. Cell populations in bronchial and bronchoalveolar lavage.

Linden M, Rasmussen JB, Piitulainen E, Larsson M, Brattsand R.

Agents Actions Suppl. 1990;30:183-97. Review.

PMID:
2239529
43.
44.

Prospects for future topical glucocorticoid development.

Brattsand R, Särnstrand B.

Acta Derm Venereol Suppl (Stockh). 1989;151:37-46; discussion 47-52.

PMID:
2624065
45.

Development of glucocorticosteroids with enhanced ratio between topical and systemic effects.

Thalén A, Brattsand R, Andersson PH.

Acta Derm Venereol Suppl (Stockh). 1989;151:11-9; discussion 47-52.

PMID:
2624062
46.

Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables.

Eklund A, Eriksson O, Håkansson L, Larsson K, Ohlsson K, Venge P, Bergstrand H, Björnson A, Brattsand R, Glennow C, et al.

Eur Respir J. 1988 Oct;1(9):832-8.

PMID:
2852604
47.

Lung and systemic thiol homeostasis during an acute lung inflammation in the rat.

Cotgreave IA, Johansson U, Moldéus P, Brattsand R.

Toxicology. 1988 Aug;50(3):331-43.

PMID:
3394158
48.

Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers.

Linden M, Wieslander E, Eklund A, Larsson K, Brattsand R.

Eur Respir J. 1988 Jul;1(7):645-50.

PMID:
2846345
49.

The anti-inflammatory activity of Ebselen but not thiols in experimental alveolitis and bronchiolitis.

Cotgreave IA, Johansson U, Westergren G, Moldéus PW, Brattsand R.

Agents Actions. 1988 Jul;24(3-4):313-9.

PMID:
2459936
50.

Human alveolar macrophages from smokers have an impaired capacity to secrete LTB4 but not other chemotactic factors.

Wieslander E, Linden M, Håkansson L, Eklund A, Blaschke E, Brattsand R, Venge P.

Eur J Respir Dis. 1987 Oct;71(4):263-72.

PMID:
2826202

Supplemental Content

Loading ...
Support Center